Compare
Bioventus Inc. vs UFP Technologies Inc vs Glaukos Corp vs NovoCure Ltd
| Latest fiscal year | Bioventus Inc. BVS | UFP Technologies Inc UFPT | Glaukos Corp GKOS | NovoCure Ltd NVCR |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $568.09M | $602.80M | $507.44M | $655.35M |
| Revenue growth (YoY) | -0.9% | +19.5% | +32.3% | +8.3% |
| Gross margin | 68.3% | 28.3% | 55.7% | 74.5% |
| Operating margin | 9.5% | 15.3% | -39.3% | -23.5% |
| Net margin | 4.0% | 11.3% | -37.0% | -20.8% |
| Net income | $22.73M | $68.31M | -$187.69M | -$136.23M |
| EPS (Diluted) | $0.33 | $8.75 | -$3.28 | -$1.22 |
| Operating cash flow | $74.67M | $91.91M | -$14.79M | -$49.03M |
| Free cash flow | $72.11M | n/a | -$22.45M | -$75.68M |
| Cash & equivalents | $51.24M | $20.30M | $90.81M | $93.55M |
| Total assets | $683.56M | $655.08M | $893.49M | $804.33M |
| Total liabilities | $455.11M | $231.20M | $237.33M | $463.86M |
| Shareholders' equity | $184.10M | $423.88M | $656.15M | $340.47M |
| Return on year-end equity | 12.3% | 16.1% | -28.6% | -40.0% |
| Shares outstanding | n/a | 7.71M | 57.51M | 112.49M |
Revenue, most recent five fiscal years
| Fiscal year | Bioventus Inc. | UFP Technologies Inc | Glaukos Corp | NovoCure Ltd |
|---|---|---|---|---|
| Latest | $568.09M Ended 2025-12-31 | $602.80M Ended 2025-12-31 | $507.44M Ended 2025-12-31 | $655.35M Ended 2025-12-31 |
| 1 year earlier | $573.28M Ended 2024-12-31 | $504.42M Ended 2024-12-31 | $383.48M Ended 2024-12-31 | $605.22M Ended 2024-12-31 |
| 2 years earlier | $512.35M Ended 2023-12-31 | $400.07M Ended 2023-12-31 | $314.71M Ended 2023-12-31 | $509.34M Ended 2023-12-31 |
| 3 years earlier | $512.12M Ended 2022-12-31 | $353.79M Ended 2022-12-31 | $282.86M Ended 2022-12-31 | $537.84M Ended 2022-12-31 |
| 4 years earlier | $430.90M Ended 2021-12-31 | $206.32M Ended 2021-12-31 | $294.01M Ended 2021-12-31 | $535.03M Ended 2021-12-31 |